Deerfield Management STAA Position
ExitedDeerfield Management exited their position in STAAR SURGICAL CO (STAA) in Q3 2024, after holding the stock for 2 quarters.
The position was first reported in Q2 2024 and has been tracked across 2 quarterly 13F filings.
Short interest stands at 24.7% of float with 5.0 days to cover, indicating significant bearish positioning against the stock.
About STAAR SURGICAL CO
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Full company profile →Short Interest
24.7%
5.0 days to cover
Deerfield Management STAA Position History
Frequently Asked Questions
Does Deerfield Management own STAA?
No. Deerfield Management exited their position in STAAR SURGICAL CO (STAA) in Q3 2024. They previously held the stock for 2 quarters.
How many hedge funds own STAA?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in STAA.
When did Deerfield Management first buy STAA?
Deerfield Management's position in STAA was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's STAA position increasing or decreasing?
Deerfield Management completely exited their STAA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
STAACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →